SHR-1806
SHR-1806 is a OX40 agonist and a NF-κB activator, with antitumor activity. SHR-1806 mediates ADCC and CDC effects, enhances the function and expansion of effector T cells, suppresses regulatory T cells, and increases γ-interferon secretion. SHR-1806 exhibits typical pharmacokinetic characteristics and favorable safety profiles. SHR-1806 can be used in studies related to solid tumors and colon cancer.
For research use only. We do not sell to patients.
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Orexin Receptor (OX Receptor) Isoforms
More
Biological Activity
Human
SHR-1806 (0.1-10000 ng/mL) binds specifically and potently to human and rhesus monkey OX40 in an ELISA format, with comparable EC50 values of 61.47 ng/mL and 60.80 ng/mL, respectively[1].
SHR-1806 (0.0001-100 nM; 1 h) exhibits potent, specific binding to OX40-expressing CHOK1-hOX40 cells and activated human T cells, with EC50 values of 1.99 nM and 0.20 nM, respectively, and no binding to activated mouse or rat T cells[1].
SHR-1806 (0.01-100 nM; 1 h) potently blocks the interaction between OX40 and OX40L in CHOK1-hOX40L cells, with an IC50 of 12.51 nM[1].
SHR-1806 (0.01-100 nM; 5 h) potently activates NF-κB signaling in Jurkat-NF-κB-Luc-hOX40 cells co-cultured with Raji cells, with an EC50 of 0.36 nM, demonstrating greater potency than GPX4[1].
SHR-1806 (1-1000 ng/mL; 72 h) potently activates human memory CD4+ T cells to secrete IFN-γ, with greater activity than the reference antibody GPX4 at equivalent concentrations[1].
SHR-1806 (0.01-100 nM; 15 min) exhibits potent ADCC activity against HEK293-hOX40 cells, with an EC50 of 0.01 nM, demonstrating superior potency compared to GPX4[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
SHR-1806 (1 mg/kg; i.p.; every 3 days; 4 total doses) at 1 mg/kg suppresses local and distant MC38 tumor growth in human OX40 knock-in mice, and enhances intratumoral effector T cell responses, with synergistic antitumor activity when combined with a TLR7 agonist[1].
SHR-1806 (0.3-1 mg/kg; i.p.; twice weekly; 3 doses then 3 additional doses) (dose-adjusted from 0.3 to 1 mg/kg) exhibits antitumor efficacy against MC38/H-11 tumors in human OX40 knock-in mice, with enhanced activity when combined with a PD-L1 inhibitor[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Human OX40 knock-in mice (maintained under SPF conditions)[1]
-
Dosage:0.3 mg/kg; 1 mg/kg; 3 mg/kg
-
Administration:i.p.; every 3 days; 6 total doses
-
Result:Demonstrated dose-dependent tumor growth inhibition with TGI values of 47.3%, 82.4%, and 90.5% at 0.3, 1, and 3 mg/kg, respectively.
Achieved a higher TGI (90.5%) than reference antibody GPX4 (78.2% TGI) at 3 mg/kg.
Increased the percentage of intratumoral CD3+ T cells, CD8+ T cells, and CD4+ T cells, and reduced the percentage of intratumoral regulatory T cells (Tregs) at 3 mg/kg compared to the control group.
Caused no significant body weight changes during treatment.
-
Animal Model:Human OX40 knock-in mice (maintained under SPF conditions)[1]
-
Dosage:1 mg/kg
-
Administration:i.p.; every 3 days; 4 total doses
-
Result:Suppressed tumor growth in both right and left flank tumors as monotherapy.
Achieved TGI of 89.0% for right-side tumors and 83.6% for left-side tumors on Day 9 post-treatment when combined with intratumoral SHR2150 (TLR7 agonist).
Increased intratumoral CD3+ T cell infiltration and the percentage of proliferating CD3+CD8+Ki67+ T cells compared to controls as monotherapy.
Caused no significant body weight changes during treatment.
TNFRSF4/OX40/CD134
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
Chemical Information
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Zhang J, et al. SHR-1806, a robust OX40 agonist to promote T cell-mediated antitumor immunity. Cancer Biol Ther. 2024;25(1):2426305. [Content Brief]
[2]. Yuan Z, et al. OX40/OX40L: a new target for tumor immunotherapy and its clinical research progress. Front Oncol. 2026;15:1730620. Published 2026 Jan 5. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)